IPR decision (Feb. 21, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Status
|
|
IPR2016-01614
|
08/15/2016
|
Celltrion, Inc.
|
Apotex Inc.
|
US 7,820,161
|
claims 1–12 are patentable
|
On US’161 patent,
Celltrion previously filed IPR (IPR2015-01744) which was denied.
Boehringer Ingelheim filed IPR (IPR2015-00415) which was terminated
(Oct 2015) as BI filed “Request for Adverse Judgment”. Pfizer also filed IPR (IPR2017-01115)
on 03/24/2017 which was instituted on 07/18/2017.
US 7,820,161 (Genentech /
Biogen; Exp: May 04, 2020)
1. A method of treating rheumatoid arthritis in a human
comprising: (a) administering to the human more than one intravenous dose of a
therapeutically effective amount of rituximab; and (b) administering to the
human methotrexate.
5. A method of treating rheumatoid arthritis in a human
comprising: (a) administering to the human more than one intravenous dose of a
therapeutically effective amount of an antibody that binds to the CD20 antigen
on human B lymphocytes; and (b) administering to the human methotrexate;
wherein the CD20 antibody administration consists of intravenous administration
of the CD20 antibody, and the CD20 antibody is rituximab.
9. A method of treating rheumatoid arthritis in a human
comprising: (a) administering to the human more than one intravenous dose of a
therapeutically effective amount of an antibody that binds to the CD20 antigen
on human B lymphocytes; and (b) administering to the human methotrexate;
wherein the therapeutically effective amount of the CD20 antibody is
administered intravenously, and the CD20 antibody is rituximab.
No comments:
Post a Comment